Table 2.
Lymph node counts stratified by ex vivo dissection
| No EVD Group | EVD Group | P Value | |
|---|---|---|---|
| Lymph Nodes Examined | 22±8.4 | 34±15.4 | <0.0001 |
| Male | 20±7.4 | 32±14.8 | <0.0001 |
| Female | 24±8.8 | 35±16.1 | 0.0002 |
| Age<60 years | 23±7.2 | 31±11.5 | 0.0009 |
| Age≥60 years | 21±9.0 | 35±17.4 | <0.0001 |
| BMI<30 kg/m2 | 23±8.3 | 33±15.8 | <0.0001 |
| BMI≥30 kg/m2 | 19±8.2 | 37±14.0 | <0.0001 |
| Well-Moderately differentiated | 19±7.0 | 26±13.5 | 0.02 |
| Poorly differentiated | 24±9.0 | 37±15.0 | <0.0001 |
| Intestinal/Mixed type | 21±8.6 | 31±14.7 | <0.0001 |
| Diffuse type | 23±7.9 | 37±15.9 | <0.0001 |
| Signet ring classification | 23±8.0 | 37±14.7 | <0.0001 |
| Lower third | 20±8.1 | 31±13.5 | <0.0001 |
| Middle third | 22±7.5 | 33±14.9 | <0.0001 |
| Upper third | 24±8.8 | 36±15.0 | <0.0001 |
| T status lymph node yield: | |||
| T0 | 21±5.5 | 27±12.4 | 0.52 |
| T1a | 16±6.0 | 31±16.4 | 0.003 |
| T1b | 22±9.4 | 27±12.4 | 0.12 |
| T2 | 24±10.4 | 36±14.5 | 0.01 |
| T3 | 23±6.7 | 35±16.2 | 0.003 |
| T4 | 23±9.2 | 41±14.7 | 0.0001 |
| N status lymph node yield: | |||
| N0 | 19±7.5 | 31±15.6 | <0.0001 |
| N1 | 24±7.3 | 36±16.3 | 0.01 |
| N2 | 25±10.4 | 32±10.7 | 0.09 |
| N3 | 28±7.1 | 41±15.2 | 0.003 |
| Stage: | |||
| I | 19±7.6 | 29±14.6 | <0.0001 |
| II | 23±9.3 | 36±16.8 | 0.001 |
| III | 25±7.8 | 39±14.4 | <0.0001 |
| Neoadjuvant chemotherapy | 23±8.0 | 33±14.2 | <0.0001 |
| No neoadjuvant chemotherapy | 20±8.5 | 34±16.9 | <0.0001 |
| Total/Subtotal Gastrectomy | 22±7.0 | 35±14.9 | <0.0001 |
| Distal Gastrectomy | 22±9.2 | 33±15.9 | <0.0001 |
| D1+ Lymphadenectomy | 10±5.7 | 32±11.2 | 0.002 |
| D2 Lymphadenectomy | 23±8.0 | 34±15.8 | <0.0001 |
| Lymph Node Positivity Rate (Positive /Total Lymph Nodes) (%) | 9.6±18.4 | 8.8±17.6 | 0.82 |